CXM - Cardium Therapeutics Inc.

Cardium Therapeutics, Inc. (Cardium), incorporated on December 22, 2003, is a medical technology company primarily focused on the development and commercialization of therapeutics and medical devices for cardiovascular and ischemic disease, wound healing and tissue repair. Cardium has established a pipeline of products that are divided into two operating units: Cardium Biologics and the Tissue Repair Company. The lead product candidate from its Cardium Biologics unit is Generx (alferminogene tadenovec, Ad5FGF-4), which is being developed as a treatment for myocardial ischemia (insufficient blood flow within the heart muscle) due to coronary heart disease. Generx represents a therapeutic class of cardiovascular biologics designed to promote collateral angiogenesis, a natural process of blood vessel growth within the heart muscle, to improve blood supply to ischemic areas of the heart following a one-time intracoronary administration.